

# TABLE OF CONTENTS

May 25, 2009

No. 2140

## BUSINESS

- 1 Novartis to Make Everolimus Blockbuster in 5 Years: Mr D. Epstein
  - Japan Participates in Global Trial of ASA404
- 2 Takeda: Record-High Sales of ¥1,538 Bil.
  - TAK-491 + Chlorthalidone Combination Enters PIII
  - Shifting Priorities in R&D from Quantity to Quality
- 3 Astellas: Growth in Sales Halted below ¥1 Tril. Mark
  - Aiming at No. 1 Share in Japan
  - Developing YM150 to Treat ACS
- 5 Daiichi Sankyo: Net Loss of ¥335.8 Bil. Due to Ranbaxy Acquisition
  - Aiming at Getting Domestic Market Share Back to 6%
  - Ranbaxy Will Not Market Generic of Cravit
  - ARB, Ca Blocker, Diuretic Combination Enters PIII in Europe
  - Daiichi Sankyo to Lead Ranbaxy in Dealing with FDA: Mr Shoda
- 7 Eisai: Profits Show Sharp Rebound with 6.5% Increase in Sales
  - NDA Filing Expected for 2 Major Products in FY2009
  - MORAb-003 Enters PIII in the US
  - Ready for Independent Marketing of Aricept
- 8 DSP: New Products Make Up for Decreases in Sales of Amlodin
  - Far Behind Goals Included in Mid-Term Management Plan
  - Future Depends on Lurasidone
  - Combination of Amlodipine and Irbesartan in PII
- 9 MTPC: Pharma Sales Up 2%; Remicade, Talion Drive Business
  - Settlement of Medway Issue No Earlier Than July
  - Applying for Additional Indication for Argatroban in Europe
- 11 Shionogi: Sales Up 6.2%; Crestor Continues to Drive Business
- 11 Ono: NHI Price Cuts, Competition with Generics Hit Business
  - Applying for Patch for AD within FY2009
- 12 Santen: Overseas Sales Affected by Strong Yen
- 13 Takeda to Acquire IDM Pharma
- 13 Shionogi to Acquire Pain-Focused US Company
- 13 Kyowa Kirin Licenses Anti-LIGHT Antibody to sanofi-aventis
- 13 IMS Health Revises Its Forecast for Global Drug Sales Downward
  - 6-10 Blockbusters Expected in 2009 and 2010

- 14 Mediceo Paltac to Invite 1,000 Employees to Early Retirement
  - *Yakkasa* Larger Than in 2004
- 15 Alfresa: Profits Plummet despite Large Increase in Sales
  - Complete Failure to Decrease Losses on Sales: President Ishiguro
- 16 **BUSINESS NEWS IN BRIEF**
  - Teijin Licenses TMX-67 to Astellas Pharma in Taiwan
  - Teikoku Seiyaku Acquires US DDS-Focused Venture
  - AZ's 1st Qtr Global Sales Driven by Crestor
- 16 **NEW PRODUCTS**
  - Kyowa Kirin: Nesp Injection Plastic Syringe

## GENERICS

- 17 First Generics Listed for 13 APIs
  - Largest Number of Products from Sawai
- 19 31 Generics of Cravit from 23 Firms Included in NHI Price List

## REGULATORY

- 20 FDA Approves ACTOplus met XR: Takeda
- 20 **REGULATORY NEWS IN BRIEF**
  - Liraglutide Receives Positive Opinion from CHMP: Novo Nordisk
  - Iressa Receives Positive Opinion for NSCLC from CHMP

## MEDICAL FACILITIES & NURSING CARE

- 21 JCR (Japan College of Rheumatology) 2009
  - Deep Remission Necessary to Suspend Treatment with Remicade: Prof. Tanaka
  - Blood IL-6 Level May Be Marker for Withdrawal of Tocilizumab: Prof. Nishimoto
  - Humira's Effects on Joint Destruction to Be Evaluated in Post-Marketing Trial
  - Humira's ADR Profile Similar to That for Infliximab, Etanercept
  - JCR Submits Data to *Koroshō* for Approval of MTX at Higher Doses

## SELF-MEDICATION

- 23 *Koroshō* to Invite Public Comments on Proposed Transient Measure
  - Council OKs Invitation of Public Comments
  - 2 Years Are Necessary to Establish Safe Marketing System: JPA
- 23 CS Yakuhin to Acquire Part of OTC Drugs Wholesale Business from Tomita Health Care